Legal & General Group
SPRY icon

Legal & General Group’s ARS Pharmaceuticals SPRY Stock Holding History

Legal & General Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
38,988
-8,897
-19% -$76.5K ﹤0.01% 2496
2026
Q1 		$385K Sell
47,885
-10,483
-18% -$100K ﹤0.01% 2430
2025
Q4 		$680K Buy
58,368
+3,125
+6% +$30.4K ﹤0.01% 2332
2025
Q3 		$555K Buy
55,243
+418
+0.8% +$6K ﹤0.01% 2423
2025
Q2 		$957K Buy
54,825
+19,484
+55% +$281K ﹤0.01% 2256
2025
Q1 		$445K Sell
35,341
-70
-0.2% -$842 ﹤0.01% 2434
2024
Q4 		$374K Buy
35,411
+1,489
+4% +$20.9K ﹤0.01% 2560
2024
Q3 		$492K Buy
33,922
+2,715
+9% +$32.3K ﹤0.01% 2463
2024
Q2 		$266K Buy
31,207
+3,550
+13% +$31.5K ﹤0.01% 2629
2024
Q1 		$283K Sell
27,657
-500
-2% -$3.73K ﹤0.01% 2621
2023
Q4 		$154K Hold
28,157
– – ﹤0.01% 2735
2023
Q3 		$106K Buy
28,157
+3,178
+13% +$20.9K ﹤0.01% 2822
2023
Q2 		$167K Sell
24,979
-39,564
-61% -$264K ﹤0.01% 2770
2023
Q1 		$420K Buy
+64,543
New +$496K ﹤0.01% 2366
2022
Q2 		– Sell
-1,642
Closed -$6K – 3647
2022
Q1 		$6K Hold
1,642
– – ﹤0.01% 3493
2021
Q4 		$11K Sell
1,642
-2,069
-56% -$16.8K ﹤0.01% 3444
2021
Q3 		$37K Buy
3,711
+2,668
+256% +$65.8K ﹤0.01% 3063
2021
Q2 		$32K Sell
1,043
-265
-20% -$8.5K ﹤0.01% 3116
2021
Q1 		$57K Buy
1,308
+1,295
+9,962% +$61.3K ﹤0.01% 2784
2020
Q4 		$1K Buy
+13
New +$434 ﹤0.01% 3478

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group's SPRY Position: Q2 2026 in Review

Legal & General Group reduced its ARS Pharmaceuticals (SPRY) stake by 19% in Q2 2026, selling an estimated $76.5K and leaving 38,988 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #2496.

Legal & General Group first reported a position in SPRY in Q4 2020 and has held it in 20 quarters since. The position peaked at $957K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Legal & General Group held 38,988 shares of ARS Pharmaceuticals worth $312K as of Q2 2026.
  • Legal & General Group sold 8,897 ARS Pharmaceuticals shares in Q2 2026, an estimated $76.5K.
  • ARS Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2496 holding.
  • Legal & General Group first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Legal & General Group's ARS Pharmaceuticals position peaked at $957K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.